Preeclampsia sFlt-1/PIGF (Soluble fms-Like Tyrosine Kinase 1/Placental Growth Factor) Ratio, Serum
Use
This test aids in risk assessment of pregnant women between 23 and 34 weeks of gestation with clinical signs and symptoms of hypertensive disorders of pregnancy that might develop preeclampsia with severe features. It is intended for use in pregnant women, with singleton pregnancies hospitalized for hypertensive disorders of pregnancy.
Special Instructions
The B路R路A路H路M路S PIGF (placental growth factor) plus KRYPTOR assay must be run in conjunction with the B路R路A路H路M路S sFlt-1 (soluble fms-like tyrosine kinase 1) KRYPTOR assay. This test is not a stand-alone test for monitoring of hypertensive disorders of pregnancy or for changing treatment, including medication.
Limitations
This test should not be used as a diagnostic tool for preeclampsia, and its effectiveness in patients with multiple pregnancies or those receiving intravenous heparin has not been established. It should not replace clinical judgment and is not intended to inform treatment changes, including medication or hospitalization.
FDA ApprovedNew York Approved
Methodology
Immunoassay (Other)
Biomarkers
LOINC Codes
- 74757-6
- 74757-6
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.3 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Patient Preparation
The patient should not receive intravenous heparin 24 hours before specimen collection.
Causes for Rejection
Gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 24 hours |
| Frozen | 180 days |